Egypt is poised to become the first Middle Eastern nation to host a biopharmaceutical manufacturing facility. Set to commence operations in the first quarter of 2025, the project is backed by a substantial EGP 5 billion investment, as revealed by Olfat Ghorab, Chairman of the Arab Company for Drug Industries & Medical Appliances (ACDIMA).
Announced during the second Global Congress on Population, Health, and Development (PHDC 2024), this fully locally funded venture aims to revolutionize the biopharmaceutical landscape by producing innovative medicines, including monoclonal antibody drugs. These therapies are crucial for enhancing the immune system’s ability to combat severe illnesses such as cancer.
The establishment of this factory is a pivotal advancement for Egypt’s healthcare sector, promising significant reductions in the cost of crucial medications. By manufacturing locally, the price of these high-demand biopharmaceuticals is expected to be cut by half compared to their imported counterparts. This price reduction could dramatically improve accessibility for Egyptian patients, providing a more affordable healthcare option within the country.
Beyond meeting local market demands, the new facility aims to position Egypt as a leader in the global pharmaceutical industry. With plans to export to over 80 countries, the factory not only underscores Egypt’s growing manufacturing capabilities but also its potential to become a central hub for biopharmaceutical innovation in the Middle East.
Olfat Ghorab emphasized the strategic importance of this development, stating, “This project is a testament to Egypt’s commitment to advancing healthcare through local innovation and developing a resilient pharmaceutical industry capable of catering to both domestic and international markets.”
This initiative also aligns with broader governmental goals to enhance economic growth through technological advancements and increased exports. As Egypt prepares to embark on this transformative journey, the nation is poised to set new standards in healthcare manufacturing, potentially inspiring similar developments across the Middle East.
